本文選題：結(jié)核 + 骨關(guān)節(jié)��； 參考：《中國組織工程研究》2016年30期

【摘要】：背景:隨著抗結(jié)核功能型骨組織工程支架研究的深入,結(jié)核性骨缺損修復(fù)成為當(dāng)前研究熱點(diǎn)之一。目的:評價(jià)抗結(jié)核功能型骨組織工程支架的制備、藥物緩釋性能和成骨性能。方法:應(yīng)用計(jì)算機(jī)檢索Pub Med數(shù)據(jù)庫、相關(guān)期刊論文、萬方數(shù)據(jù)庫中,相關(guān)功能型骨組織工程支架修復(fù)結(jié)核性骨缺損的文章,中文檢索詞為"骨組織工程支架,結(jié)核,骨缺損",英文檢索詞為"Bone tissue engineering scaffold,Tuberculosis,Bone defect"。結(jié)果與結(jié)論:抗結(jié)核功能型骨組織工程支架具有較好的藥物緩釋性能、組織相容性、成骨性能及抗結(jié)核桿菌性能,能長時(shí)間穩(wěn)定釋放藥物,增強(qiáng)局部應(yīng)用抗結(jié)核藥的效果,解決臨床上結(jié)核性骨缺損修復(fù)困難易復(fù)發(fā)的難題。目前,研制的抗結(jié)核性骨組織工程支架還未達(dá)到臨床需求。首先,針對結(jié)核分枝桿菌的多藥物聯(lián)合治療常需3或4種抗結(jié)核藥物的聯(lián)合使用,而目前抗結(jié)核性骨組織工程支架只能達(dá)到聯(lián)合2種藥物;其次,抗結(jié)核治療療程常需6-12個(gè)月,現(xiàn)有的抗結(jié)核性骨組織工程支架藥物釋放時(shí)還不能滿足該需求;制備抗結(jié)核性骨組織工程支架材料的文獻(xiàn)居多,但應(yīng)用此種材料在結(jié)核動物模型進(jìn)行的驗(yàn)證實(shí)驗(yàn)缺失。關(guān)鍵詞:
[Abstract]:Background: with the development of anti-tuberculosis functional bone tissue engineering scaffolds, the repair of tuberculous bone defects has become one of the hotspots. Objective: to evaluate the preparation, drug release and osteogenesis of anti-tuberculosis functional bone tissue engineering scaffolds. Methods: the relevant functional bone tissue engineering scaffolds for repairing tuberculous bone defects were searched by computer in Pub Med database, full text database of Chinese periodicals and Wanfang database. The Chinese key words were "bone tissue engineering scaffold, tuberculosis, tuberculosis". Bone tissue engineering scaffold was used as bone defect. Results and conclusion: the anti-tuberculosis functional bone tissue engineering scaffold has good drug release ability, histocompatibility, osteogenic property and anti-tuberculous bacilli performance. It can release drugs stably for a long time and enhance the effect of local application of anti-tuberculosis drugs. To solve the clinical tuberculous bone defect repair difficulties and recurrence problems. At present, the anti-tuberculous bone tissue engineering scaffold has not met the clinical requirements. First, the multi-drug combination therapy for Mycobacterium tuberculosis often requires three or four anti-tuberculosis drugs, but at present, the anti-tuberculous bone tissue engineering stent can only combine two drugs; secondly, the course of anti-tuberculosis treatment often takes 6-12 months. The current anti-tuberculous bone tissue engineering stents drug release can not meet this demand; the preparation of anti-tuberculous bone tissue engineering scaffold materials literature is the majority, but the application of this material in the animal model of tuberculosis validation is missing. Keywords:
【作者單位】： 慶陽市人民醫(yī)院骨二科;甘肅省第二人民醫(yī)院骨科;解放軍蘭州軍區(qū)蘭州總醫(yī)院全軍骨科中心;
【基金】：國家自然科學(xué)基金(81371983):多孔β-TCP負(fù)載聚乳酸羥基乙酸共聚物抗結(jié)核藥物緩釋微球的構(gòu)建及其抗結(jié)核成骨作用研究~~
【分類號】：R68;R318.08
，

本文編號：2035835